Taimoor Hashim, MD
Interventional Cardiology · Montgomery, ALNPI 1487867172
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Boston Scientific at 31.5% of the total. Reporting peaked in 2022 at $4,481 and has fallen 89.5% since, to $468 in 2025.
Across 271 payments — averaging $45.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- Abbott$2K
- Medtronic$1K
- Medical Device Business Services, Inc.$1K
- E.r. Squibb & Sons, L.L.C.$474
- Novartis$454
- plus $2K from 26 others
What the payments were for
- Travel & lodging$6,76855%
- Food & beverage$5,51645%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 30 | $3,874 |
| Abbott | 36 | $2,415 |
| Medtronic(2 entities) | 7 | $1,473 |
| Medical Device Business Services, Inc. | 6 | $1,170 |
| E.r. Squibb & Sons, L.L.C. | 23 | $474 |
| Novartis | 32 | $454 |
| Johnson & Johnson | 33 | $449 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $411 |
| Pfizer | 14 | $236 |
| Amgen | 13 | $215 |
| United Therapeutics Corporation | 9 | $126 |
| Boehringer Ingelheim | 7 | $120 |
| Abiomed | 1 | $119 |
| AstraZeneca | 6 | $87 |
| Sanofi-aventis U.S. LLC | 4 | $73 |
| Actelion Pharmaceuticals US, Inc. | 3 | $53 |
| Akcea Therapeutics, Inc. | 2 | $50 |
| Alnylam Pharmaceuticals Inc. | 2 | $49 |
| Bayer | 2 | $48 |
| Biotronik Inc. | 3 | $47 |
| Edwards Lifesciences | 2 | $47 |
| Irhythm Technologies, Inc. | 2 | $46 |
| Lexicon Pharmaceuticals, Inc. | 2 | $38 |
| Philips North America LLC | 2 | $33 |
| Baxter Healthcare | 1 | $33 |
| Cvrx, Inc. | 2 | $32 |
| Merck | 2 | $31 |
| Shockwave Medical, Inc | 1 | $26 |
| Inari Medical, Inc. | 1 | $21 |
| Bridgebio Pharma, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Inogen, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VersaCross Access Solution$1,932
- XACT$1,236
- Micra$1,182
- Carto 3$1,111
- GENERAL - THERAPIES$1,088
- ONYX FRONTIER$172
- ESPRIT$124
How this compares
$12,305 in reported general payments places this provider in the 70th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 298 | $247,247 |
| EntrestoSacubitril/Valsartan | 90 | $75,940 |
| XareltoRivaroxaban | 62 | $59,505 |
| BrilintaTicagrelor | 34 | $19,767 |
| Repatha SureclickEvolocumab | 29 | $18,249 |
| FarxigaDapagliflozin Propanediol | 19 | $16,761 |
| OzempicSemaglutide | 12 | $15,582 |
| Ranolazine ErRanolazine | 89 | $6,913 |
| Prasugrel Hcl | 48 | $6,905 |
| Atorvastatin Calcium | 255 | $4,086 |
| Metoprolol Succinate | 169 | $2,741 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 91 | $2,046 |
| Carvedilol | 195 | $1,888 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 13 | $1,620 |
| ClopidogrelClopidogrel Bisulfate | 134 | $1,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $236 | $247,247298 claims |
| NovartisEntresto | $454 | $75,94090 claims |
| Johnson & JohnsonXarelto | $449 | $59,50562 claims |
| AstraZenecaBrilinta, Farxiga | $87 | $36,52753 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Montgomery
- Sergio Perez BeracasaMontgomery$25K
- John KolawoleMontgomery$23K
- Thomas WoolMontgomery$8K
- Ashwini SharmaMontgomery$8K
- Gary RoubinBirmingham$157K
- Michael ButlerHuntsville$109K
- Pochana ReddyHuntsville$100K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
- John GallaMobile$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.